跳至主要内容
临床试验/IRCT2015020110326N2
IRCT2015020110326N2已完成2 期

Efficacy of Captophyte compound in comparison with Captopril alone on blood pressure in patients with essential hypertension

Vice Chancellor for Research & Technology, Hormozgan University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 years 至 55 years(—)
性别
All

入选标准

  • essential hypertension; age of 20 - 55 years and no response to diet and exercise in prehypertension state.
  • Exclusion criteria: one or more of the following:
  • Creatinine levels > 1.5 mg/dl; elevated liver enzymes; intake of any of the anti-hypertensive medications (nitrates, beta blockers, anhydrase carbonic inhibitors, calcium channel blockers, diuretics and angiotensin receptor blocker) due any other underlying medical causes; concurrent intake of any medications having hepatic metabolism (with super enzymes of cytochrome p450 including CYP2D6 (i.e. imipramine, fluoxetine, promethazine, celcoxib, hydroxyzine, citalopram, dextrometorphan, codeine, ondansetron, tamoxifen, tarmadol ). CYP3A4 (clarythromycin, erythromycin, cimetidine, carbamazepine, phenytoin, phenobarbital, rifampin, corticosteroids, atorvastatin, benzodiazepines, and haloperidol) which metabolize most of BB, CCB, ACEI, ARB; medication with warfarin; other cardiovascular complications such as angina pectoris, IHD, hypertensive crisis, or cerebrovascular accidents such as TIA, or stroke which require CCB, BB, ACE; GI disturbances; allergic reactions; immunologic reactions; unwillingness to participate in the study; death of the patient.

排除标准

  • 未提供

研究者

发起方
Vice Chancellor for Research & Technology, Hormozgan University of Medical Sciences

相似试验

Efficacy of Captophyte compound in comparison with... | 临床试验